Shots:
- Insitro to receive $50M as up front, $20M as near-term operational milestones and is eligible to receive ~$2B+ as discovery, development, regulatory and commercial milestones along with royalties on sales of the therapies
- BMS will lead the clinical development, regulatory submissions, and commercialization activities. Insitro will apply its insitro Human (ISH) platform, to create iPSC derived disease models for ALS and FTD
- Insitro will apply ML-enabled therapeutics discovery capabilities to advance programs while BMS to get an option to select several targets identified by insitro to advance through clinical development and commercialization
Click here to read full press release/ article | Ref: Businesswire | Image: Medium
The post BMS Signs a Five-Year Agreement with Insitro to Develop Therapies for ALS and Frontotemporal Dementia first appeared on PharmaShots.
